243 related articles for article (PubMed ID: 16354195)
1. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
Yang G; Rajadurai A; Tsao H
J Invest Dermatol; 2005 Dec; 125(6):1242-51. PubMed ID: 16354195
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas.
Kaune KM; Neumann C; Hallermann C; Haller F; Schön MP; Middel P
Exp Dermatol; 2011 Apr; 20(4):331-5. PubMed ID: 21410763
[TBL] [Abstract][Full Text] [Related]
3. Dual inactivation of RB and p53 pathways in RAS-induced melanomas.
Bardeesy N; Bastian BC; Hezel A; Pinkel D; DePinho RA; Chin L
Mol Cell Biol; 2001 Mar; 21(6):2144-53. PubMed ID: 11238948
[TBL] [Abstract][Full Text] [Related]
4. Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers.
Pacifico A; Goldberg LH; Peris K; Chimenti S; Leone G; Ananthaswamy HN
Br J Dermatol; 2008 Feb; 158(2):291-7. PubMed ID: 18070208
[TBL] [Abstract][Full Text] [Related]
5. P16 UV mutations in human skin epithelial tumors.
Soufir N; Molès JP; Vilmer C; Moch C; Verola O; Rivet J; Tesniere A; Dubertret L; Basset-Seguin N
Oncogene; 1999 Sep; 18(39):5477-81. PubMed ID: 10498902
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.
Sanchez-Cespedes M; Reed AL; Buta M; Wu L; Westra WH; Herman JG; Yang SC; Jen J; Sidransky D
Oncogene; 1999 Oct; 18(43):5843-9. PubMed ID: 10557071
[TBL] [Abstract][Full Text] [Related]
7. Combined analysis of p53 and RB pathways in epithelial ovarian cancer.
Hashiguchi Y; Tsuda H; Yamamoto K; Inoue T; Ishiko O; Ogita S
Hum Pathol; 2001 Sep; 32(9):988-96. PubMed ID: 11567230
[TBL] [Abstract][Full Text] [Related]
8. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
9. Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth.
Williams RT; Barnhill LM; Kuo HH; Lin WD; Batova A; Yu AL; Diccianni MB
PLoS One; 2014; 9(2):e88219. PubMed ID: 24505435
[TBL] [Abstract][Full Text] [Related]
10. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma.
Koenig A; Bianco SR; Fosmire S; Wojcieszyn J; Modiano JF
Vet Pathol; 2002 Jul; 39(4):458-72. PubMed ID: 12126149
[TBL] [Abstract][Full Text] [Related]
11. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
12. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
Nielsen GP; Burns KL; Rosenberg AE; Louis DN
Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
[TBL] [Abstract][Full Text] [Related]
13. CDKN2A/p16 is inactivated in most melanoma cell lines.
Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
[TBL] [Abstract][Full Text] [Related]
14. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
15. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
[TBL] [Abstract][Full Text] [Related]
16. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes.
Soufir N; Bressac-de Paillerets B; Desjardins L; Lévy C; Bombled J; Gorin I; Schlienger P; Stoppa-Lyonnet D
Br J Cancer; 2000 Feb; 82(4):818-22. PubMed ID: 10732752
[TBL] [Abstract][Full Text] [Related]
17. Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B.
Soto JL; Cabrera CM; Serrano S; López-Nevot MA
BMC Cancer; 2005 Apr; 5():36. PubMed ID: 15819981
[TBL] [Abstract][Full Text] [Related]
18. A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF.
Hashemi J; Lindström MS; Asker C; Platz A; Hansson J; Wiman KG
Cancer Lett; 2002 Jun; 180(2):211-21. PubMed ID: 12175554
[TBL] [Abstract][Full Text] [Related]
19. Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica.
Sherburn TE; Gale JM; Ley RD
DNA Cell Biol; 1998 Nov; 17(11):975-81. PubMed ID: 9839807
[TBL] [Abstract][Full Text] [Related]
20. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
